سماگلوتاید (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "سماگلوتاید" in Persian language version.

refsWebsite

Global rank Persian rank

22web.archive.org

1^st place

19nih.gov

4^th place

5^th place

12doi.org

2^nd place

5europa.eu

68^th place

179^th place

3tga.gov.au

3,984^th place

1,143^rd place

3hres.ca

low place

2medicines.org.uk

3,823^rd place

1,188^th place

2clincalc.com

3,912^th place

779^th place

2washingtonpost.com

34^th place

90^th place

1funnelback.com

low place

1qut.edu.au

8,570^th place

low place

1rxlist.com

7,927^th place

2,299^th place

1nytimes.com

7^th place

24^th place

1nice.org.uk

3,258^th place

1,207^th place

clincalc.com

"The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 7 October 2022.
"Semaglutide – Drug Usage Statistics". ClinCalc. Archived from the original on 8 October 2022. Retrieved 7 October 2022.

doi.org

Singh G, Krauthamer M, Bjalme-Evans M (January 2022). "Wegovy (semaglutide): a new weight loss drug for chronic weight management". Journal of Investigative Medicine. 70 (1): 5–13. doi:10.1136/jim-2021-001952. PMC 8717485. PMID 34706925.
Phillips A, Clements JN (February 2022). "Clinical review of subcutaneous semaglutide for obesity". Journal of Clinical Pharmacy and Therapeutics. 47 (2): 184–193. doi:10.1111/jcpt.13574. PMID 34964141.
Amaro A, Sugimoto D, Wharton S (January 2022). "Efficacy and safety of semaglutide for weight management: evidence from the STEP program". Postgraduate Medicine. 134 (sup1): 5–17. doi:10.1080/00325481.2022.2147326. PMID 36691309.
Doggrell SA (March 2018). "Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?" (PDF). Expert Opinion on Drug Metabolism & Toxicology. 14 (3): 371–377. doi:10.1080/17425255.2018.1441286. PMID 29439603. Archived from the original (PDF) on 5 May 2020. Retrieved 12 December 2019. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «doggrell» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).
Goldenberg RM, Steen O (March 2019). "Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes". Canadian Journal of Diabetes. 43 (2): 136–145. doi:10.1016/j.jcjd.2018.05.008. PMID 30195966. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «goldenberg» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).
Hughes S, Neumiller JJ (January 2020). "Oral Semaglutide". Clinical Diabetes. 38 (1): 109–111. doi:10.2337/cd19-0079. PMC 6969659. PMID 31975761.
Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M (October 2023). "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss". JAMA. doi:10.1001/jama.2023.19574. PMC 10557026. PMID 37796527.
Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, Mølck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M, Moerch U (April 2010). "Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation". Endocrinology. 151 (4): 1473–1486. doi:10.1210/en.2009-1272. PMID 20203154.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T (November 2016). "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes". The New England Journal of Medicine. 375 (19): 1834–1844. doi:10.1056/NEJMoa1607141. PMID 27633186.
Li Y, Hansotia T, Yusta B, Ris F, Halban P, Drucker D (2003). "Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis". The Journal of Biological Chemistry. 278 (1): 471–478. doi:10.1074/jbc.M209423200. PMID 12409292.
Dhillon S (February 2018). "Semaglutide: First Global Approval". Drugs. 78 (2): 275–284. doi:10.1007/s40265-018-0871-0. PMID 29363040.
Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB (September 2017). "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity". Diabetes, Obesity & Metabolism. 19 (9): 1242–1251. doi:10.1111/dom.12932. PMC 5573908. PMID 28266779.

europa.eu

ema.europa.eu

"Ozempic EPAR". آژانس دارویی اروپا (EMA). 17 September 2018. Archived from the original on 25 October 2020. Retrieved 26 September 2020.
"Rybelsus EPAR". آژانس دارویی اروپا (EMA). 29 January 2020. Archived from the original on 14 August 2020. Retrieved 26 September 2020.
"Wegovy EPAR". European Medicines Agency. 11 November 2021. Archived from the original on 2 July 2022. Retrieved 11 March 2022. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «Wegovy EPAR» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).
"Wegovy: Pending EC decision". European Medicines Agency. 11 November 2021. Archived from the original on 13 November 2021. Retrieved 13 November 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

ec.europa.eu

"Wegovy Product information". Union Register of medicinal products. Archived from the original on 30 October 2022. Retrieved 3 March 2023.

funnelback.com

tga-search.clients.funnelback.com

"Summary for ARTG Entry: 346198 Rybelsus semaglutide 3 mg tablet blister pack". Therapeutic Goods Administration (TGA). Archived from the original on 24 February 2022. Retrieved 23 February 2022.

hres.ca

pdf.hres.ca

Product Monograph Including Patient Medication Information – Ozempic semaglutide injection (PDF) (Report). Novo-Nordisk Canada. 21 August 2020 [Initial approval 4 January 2018]. Archived (PDF) from the original on 7 June 2021. Retrieved 6 June 2021.
Product Monograph Including Patient Medication Information – Rybelsus semaglutide tablets (PDF) (Report). Novo-Nordisk Canada. 30 March 2020. Archived (PDF) from the original on 14 December 2021. Retrieved 6 June 2021.

hpr-rps.hres.ca

"Regulatory Decision Summary – Rybelsus". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.

medicines.org.uk

"Ozempic 0.25 mg solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC)". (emc). 9 April 2021. Archived from the original on 6 June 2021. Retrieved 6 June 2021.
"Rybelsus – Summary of Product Characteristics (SmPC)". (emc). 25 November 2020. Archived from the original on 6 June 2021. Retrieved 6 June 2021.

nice.org.uk

"NICE recommended weight-loss drug to be made available in specialist NHS services". انستیتوی ملی تعالی سلامت و مراقبت (NICE). 8 March 2023. Archived from the original on 9 March 2023.

nih.gov

pubmed.ncbi.nlm.nih.gov

Singh G, Krauthamer M, Bjalme-Evans M (January 2022). "Wegovy (semaglutide): a new weight loss drug for chronic weight management". Journal of Investigative Medicine. 70 (1): 5–13. doi:10.1136/jim-2021-001952. PMC 8717485. PMID 34706925.
Phillips A, Clements JN (February 2022). "Clinical review of subcutaneous semaglutide for obesity". Journal of Clinical Pharmacy and Therapeutics. 47 (2): 184–193. doi:10.1111/jcpt.13574. PMID 34964141.
Amaro A, Sugimoto D, Wharton S (January 2022). "Efficacy and safety of semaglutide for weight management: evidence from the STEP program". Postgraduate Medicine. 134 (sup1): 5–17. doi:10.1080/00325481.2022.2147326. PMID 36691309.
Doggrell SA (March 2018). "Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?" (PDF). Expert Opinion on Drug Metabolism & Toxicology. 14 (3): 371–377. doi:10.1080/17425255.2018.1441286. PMID 29439603. Archived from the original (PDF) on 5 May 2020. Retrieved 12 December 2019. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «doggrell» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).
Goldenberg RM, Steen O (March 2019). "Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes". Canadian Journal of Diabetes. 43 (2): 136–145. doi:10.1016/j.jcjd.2018.05.008. PMID 30195966. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «goldenberg» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).
Hughes S, Neumiller JJ (January 2020). "Oral Semaglutide". Clinical Diabetes. 38 (1): 109–111. doi:10.2337/cd19-0079. PMC 6969659. PMID 31975761.
Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M (October 2023). "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss". JAMA. doi:10.1001/jama.2023.19574. PMC 10557026. PMID 37796527.
Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, Mølck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M, Moerch U (April 2010). "Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation". Endocrinology. 151 (4): 1473–1486. doi:10.1210/en.2009-1272. PMID 20203154.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T (November 2016). "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes". The New England Journal of Medicine. 375 (19): 1834–1844. doi:10.1056/NEJMoa1607141. PMID 27633186.
Li Y, Hansotia T, Yusta B, Ris F, Halban P, Drucker D (2003). "Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis". The Journal of Biological Chemistry. 278 (1): 471–478. doi:10.1074/jbc.M209423200. PMID 12409292.
Dhillon S (February 2018). "Semaglutide: First Global Approval". Drugs. 78 (2): 275–284. doi:10.1007/s40265-018-0871-0. PMID 29363040.
Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB (September 2017). "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity". Diabetes, Obesity & Metabolism. 19 (9): 1242–1251. doi:10.1111/dom.12932. PMC 5573908. PMID 28266779.

ncbi.nlm.nih.gov

Singh G, Krauthamer M, Bjalme-Evans M (January 2022). "Wegovy (semaglutide): a new weight loss drug for chronic weight management". Journal of Investigative Medicine. 70 (1): 5–13. doi:10.1136/jim-2021-001952. PMC 8717485. PMID 34706925.
Hughes S, Neumiller JJ (January 2020). "Oral Semaglutide". Clinical Diabetes. 38 (1): 109–111. doi:10.2337/cd19-0079. PMC 6969659. PMID 31975761.
Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M (October 2023). "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss". JAMA. doi:10.1001/jama.2023.19574. PMC 10557026. PMID 37796527.
Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB (September 2017). "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity". Diabetes, Obesity & Metabolism. 19 (9): 1242–1251. doi:10.1111/dom.12932. PMC 5573908. PMID 28266779.

dailymed.nlm.nih.gov

"Ozempic- semaglutide injection, solution". DailyMed. Archived from the original on 5 June 2021. Retrieved 5 June 2021. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «Ozempic FDA label» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).
"Rybelsus- oral semaglutide tablet". DailyMed. Archived from the original on 5 June 2021. Retrieved 5 June 2021. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «Rybelsus FDA label» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).
"Wegovy- semaglutide injection, solution". DailyMed. 4 June 2021. Archived from the original on 14 December 2021. Retrieved 11 March 2022. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «Wegovy FDA label» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).

nytimes.com

"Patients Taking Experimental Obesity Drug Lost More Than 50 Pounds, Maker Claims". نیویورک تایمز. 28 April 2022. Archived from the original on 27 June 2022. Retrieved 13 May 2022.

qut.edu.au

eprints.qut.edu.au

Doggrell SA (March 2018). "Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?" (PDF). Expert Opinion on Drug Metabolism & Toxicology. 14 (3): 371–377. doi:10.1080/17425255.2018.1441286. PMID 29439603. Archived from the original (PDF) on 5 May 2020. Retrieved 12 December 2019. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «doggrell» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).

rxlist.com

"Side Effects of Wegovy (Semaglutide Injection), Warnings, Uses". RxList (part of the وب‌ام‌دی network). 18 January 2023. Archived from the original on 9 March 2023. Retrieved 9 March 2023.

tga.gov.au

"Rybelsus APMDS". Therapeutic Goods Administration (TGA). 22 February 2022. Retrieved 23 February 2022.
"Rybelsus APMDS". Therapeutic Goods Administration (TGA). 22 February 2022. Retrieved 23 February 2022.
"WEGOVY (Novo Nordisk Pharmaceuticals Pty Ltd)". Therapeutic Goods Administration (TGA). 7 October 2022. Archived from the original on 14 April 2023. Retrieved 7 April 2023.

washingtonpost.com

"Insurers clamping down on doctors who prescribe Ozempic for weight loss". 12 June 2023. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «Gilbert» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).
"I lost 40 pounds on Ozempic. But I'm left with even more questions". واشینگتن پست. 6 June 2023. Archived from the original on 7 June 2023.

web.archive.org

"Summary for ARTG Entry: 346198 Rybelsus semaglutide 3 mg tablet blister pack". Therapeutic Goods Administration (TGA). Archived from the original on 24 February 2022. Retrieved 23 February 2022.
"WEGOVY (Novo Nordisk Pharmaceuticals Pty Ltd)". Therapeutic Goods Administration (TGA). 7 October 2022. Archived from the original on 14 April 2023. Retrieved 7 April 2023.
Product Monograph Including Patient Medication Information – Ozempic semaglutide injection (PDF) (Report). Novo-Nordisk Canada. 21 August 2020 [Initial approval 4 January 2018]. Archived (PDF) from the original on 7 June 2021. Retrieved 6 June 2021.
Product Monograph Including Patient Medication Information – Rybelsus semaglutide tablets (PDF) (Report). Novo-Nordisk Canada. 30 March 2020. Archived (PDF) from the original on 14 December 2021. Retrieved 6 June 2021.
"Regulatory Decision Summary – Rybelsus". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.
"Ozempic 0.25 mg solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC)". (emc). 9 April 2021. Archived from the original on 6 June 2021. Retrieved 6 June 2021.
"Rybelsus – Summary of Product Characteristics (SmPC)". (emc). 25 November 2020. Archived from the original on 6 June 2021. Retrieved 6 June 2021.
"Ozempic- semaglutide injection, solution". DailyMed. Archived from the original on 5 June 2021. Retrieved 5 June 2021. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «Ozempic FDA label» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).
"Rybelsus- oral semaglutide tablet". DailyMed. Archived from the original on 5 June 2021. Retrieved 5 June 2021. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «Rybelsus FDA label» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).
"Wegovy- semaglutide injection, solution". DailyMed. 4 June 2021. Archived from the original on 14 December 2021. Retrieved 11 March 2022. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «Wegovy FDA label» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).
"Ozempic EPAR". آژانس دارویی اروپا (EMA). 17 September 2018. Archived from the original on 25 October 2020. Retrieved 26 September 2020.
"Rybelsus EPAR". آژانس دارویی اروپا (EMA). 29 January 2020. Archived from the original on 14 August 2020. Retrieved 26 September 2020.
"Wegovy EPAR". European Medicines Agency. 11 November 2021. Archived from the original on 2 July 2022. Retrieved 11 March 2022. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «Wegovy EPAR» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).
Doggrell SA (March 2018). "Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?" (PDF). Expert Opinion on Drug Metabolism & Toxicology. 14 (3): 371–377. doi:10.1080/17425255.2018.1441286. PMID 29439603. Archived from the original (PDF) on 5 May 2020. Retrieved 12 December 2019. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «doggrell» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).
"The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 7 October 2022.
"Semaglutide – Drug Usage Statistics". ClinCalc. Archived from the original on 8 October 2022. Retrieved 7 October 2022.
"Side Effects of Wegovy (Semaglutide Injection), Warnings, Uses". RxList (part of the وب‌ام‌دی network). 18 January 2023. Archived from the original on 9 March 2023. Retrieved 9 March 2023.
"Wegovy: Pending EC decision". European Medicines Agency. 11 November 2021. Archived from the original on 13 November 2021. Retrieved 13 November 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Wegovy Product information". Union Register of medicinal products. Archived from the original on 30 October 2022. Retrieved 3 March 2023.
"Patients Taking Experimental Obesity Drug Lost More Than 50 Pounds, Maker Claims". نیویورک تایمز. 28 April 2022. Archived from the original on 27 June 2022. Retrieved 13 May 2022.
"NICE recommended weight-loss drug to be made available in specialist NHS services". انستیتوی ملی تعالی سلامت و مراقبت (NICE). 8 March 2023. Archived from the original on 9 March 2023.
"I lost 40 pounds on Ozempic. But I'm left with even more questions". واشینگتن پست. 6 June 2023. Archived from the original on 7 June 2023.